Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia
Authors:
- Won-Myong BahkWBWon-Myong Bahk
- Hyun-Sang ChoHCHyun-Sang Cho
- Yang-Whan JeonYJYang-Whan Jeon
- Duk-In JonDJDuk-In Jon
- Hee-Yeon JungHJHee-Yeon Jung
- Chan-Hyung KimCKChan-Hyung Kim
- Hee-Cheol KimHKHee-Cheol Kim
- Yong-Ku KimYKYong-Ku Kim
- Young-Hoon KimYKYoung-Hoon Kim
- Jun-Soo KwonJKJun-Soo Kwon
- Sang-Yeol LeeSLSang-Yeol Lee
- 1 July 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 33 (4) , 169-175
Abstract
The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was -23.48 +/- 19.73 for the blonanserin group and -25.40 +/- 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.Keywords
This publication has 17 references indexed in Scilit:
- The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase SchizophreniaCNS Drugs, 2009
- The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trialsJournal of Affective Disorders, 2009
- Efficacy of Iloperidone in the Treatment of SchizophreniaJournal of Clinical Psychopharmacology, 2008
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- Efficacy and Tolerability of Ziprasidone Versus Risperidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2004
- Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brainLife Sciences, 2004
- Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in miceNeuroReport, 2003
- Metric characteristics of the drug‐induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug‐induced movement disordersMovement Disorders, 2002
- Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse BrainActa Pharmacologica et Toxicologica, 1963
- The Brief Psychiatric Rating ScalePsychological Reports, 1962